Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/acr.25499 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Data Insights on the Risks of Local Heat and Massage in Gouty Arthritis Treatment.
J Orthop Case Rep
January 2025
Arthritis and Breast Care Centre, Kurukshetra, Haryana, India.
Introduction: Gouty arthritis is a common inflammatory condition caused by the deposition of uric acid crystals in the joints, leading to intense pain, swelling, and functional impairment. Thermal therapies, including hot and cold fomentation, are often used as adjunctive treatments for managing inflammation and pain in various musculoskeletal conditions. However, the efficacy of these therapies in acute gout remains underexplored.
View Article and Find Full Text PDFGout flare prophylaxis trials: comment on the article by Maher et al.
Arthritis Care Res (Hoboken)
January 2025
Rutgers Ernest Mario School of Pharmacy, Piscataway, New Jersey.
Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression.
Endocrinol Diabetes Nutr (Engl Ed)
January 2025
Francesc de Borja Hospital, Gandía, Spain.
Introduction: Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) were shown to lower hyperuricemic events in patients with type 2 diabetes mellitus (T2DM), the extent of this effect in the general population is yet to be elucidated. We performed an updated systematic review and meta-analysis on a large sample of patients with and without T2DM to evaluate the influence of SGLT2i therapy on clinically relevant hyperuricemic events, defined as the composite of acute gout flare episodes, acute anti-gout management or urate-lowering therapy initiation. Furthermore, we conducted a multivariate meta-regression to assess the relationship between different covariates and the pooled effect size.
View Article and Find Full Text PDFTreatment-Emergent Major Adverse Cardiovascular and Thromboembolic Events were Infrequent During Clinical Trials of Pegloticase.
Rheumatology (Oxford)
January 2025
Amgen Inc, Thousand Oaks, CA, USA.
Objectives: Long-term maintenance of serum urate (SU) levels <6 mg/dl reduces gout flare frequency. However, urate-lowering therapy (ULT) initiation can induce gout flare. The incidence of thromboembolic (TE) and cardiovascular (CV) events has been shown to increase in the 30 and 120 days following gout flare, respectively; therefore, the question of ULT initiation increasing patient risk for CV/TE events has been raised.
View Article and Find Full Text PDFGout and Hyperuricemia: A Narrative Review of Their Comorbidities and Clinical Implications.
J Clin Med
December 2024
Department of Rheumatology, Päijät-Häme Central Hospital, Wellbeing Services County of Päijät-Häme, 15850 Lahti, Finland.
Gout is the most common form of inflammatory arthritis, caused by the deposition of monosodium urate crystals in the joints due to elevated serum uric acid levels. Its prevalence and associated healthcare burden have been rising in recent decades, a trend expected to continue. It is crucial to recognize that gout and hyperuricemia are not merely causes of painful joint flares, but systemic metabolic disorders linked to a broad spectrum of comorbidities such as cardiovascular diseases, chronic kidney disease, diabetes, insulin resistance, steatotic liver disease, osteoarthritis, and respiratory and eye diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!